Table 1.
Demographic data and clinical characteristics of patients initially included in the study (n = 50) and those who were followed during the entire study (n = 40).
| Clinical variables | 7–15 weeks after dose 2 (n = 50) | 3 months after dose 3 (n = 40) |
|---|---|---|
| Age (years) | 69.4 ± 14.1 (25, 90) | 70.6 ± 12.5 (42, 90) |
| Men/women | 31/19, 62%/38% | 25/15, 67%/33% |
| Body mass index (BMI, kg/m2) | 26.1 ± 5.6 (13, 44) | 26.3 ± 6.1 (13, 44) |
| Dialysis duration at study start (months) | 65.1 ± 74.0 (5, 470) | 69.1 ± 79.8 (5, 470) |
| Diabetes mellitus (DM) (n, %) | 23 (46) | 19 (48) |
| Nefrosclerosis (n, %) | 15 (30) | 10 (25) |
| Autosomal dominant polycystic disease (n, %) | 4 (8) | 3 (8) |
| Chronic glomerulonephritis (n, %) | 8 (16) | 7 (18) |
| Vasculitis/anti-GBM-nephropathy (n, %) | 4 (8) | 3 (8) |
| Ongoing medication with CNIs (n, %) | 1 (2) | 1 (2) |
| Ongoing medication with MMF (n, %) | 1 (2) | 1 (2) |
| Previous treatment with CNI (n, %) | 2 (4) | 1 (2) |
| Previous treatment with rituximab or cyclophosphamide (n, %) | 5 (10) | 4 (10) |
| Current steroid treatment (n, %) | 7 (14) | 7 (18) |
CNI; calcineurin inhibitor, GBM; glomerular basement; MMF: mycophenolate mofetil.